

# SFRS2 Antibody (N-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP2800a

## **Product Information**

**Application** WB, IHC-P, E **Primary Accession** Q01130

Other Accession <u>Q6PDU1</u>, <u>Q06A98</u>, <u>Q62093</u>, <u>P30352</u>, <u>Q3MHR5</u>

Reactivity Human

**Predicted** Mouse, Rat, Pig, Chicken, Bovine

Host Rabbit
Clonality Polyclonal
Isotype Rabbit IgG
Clone Names RB17329
Calculated MW 25476
Antigen Region 9-39

# **Additional Information**

Gene ID 6427

Other Names Serine/arginine-rich splicing factor 2, Protein PR264, Splicing component, 35

kDa, Splicing factor SC35, SC-35, Splicing factor, arginine/serine-rich 2, SRSF2,

SFRS2

**Target/Specificity** This SFRS2 antibody is generated from rabbits immunized with a KLH

conjugated synthetic peptide between 9-39 amino acids from the N-terminal

region of human SFRS2.

**Dilution** WB~~1:1000 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.

**Format** Purified polyclonal antibody supplied in PBS with 0.05% (V/V) Proclin 300. This

antibody is purified through a protein A column, followed by peptide affinity

purification.

**Storage** Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions** SFRS2 Antibody (N-term) is for research use only and not for use in diagnostic

or therapeutic procedures.

### **Protein Information**

Name SRSF2

Synonyms SFRS2

#### **Function**

Necessary for the splicing of pre-mRNA. It is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. Interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. Binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3'. Can bind to beta-globin mRNA and commit it to the splicing pathway. The phosphorylated form (by SRPK2) is required for cellular apoptosis in response to cisplatin treatment.

#### **Cellular Location**

Nucleus. Nucleus, nucleoplasm. Nucleus speckle. Note=Phosphorylation by SRPK2 provokes its redistribution from the nuclear speckle to nucleoplasm


# **Background**

SFRS2 is necessary for the splicing of pre-mRNA. The protein is required for formation of the earliest ATP-dependent splicing complex and interacts with spliceosomal components bound to both the 5'- and 3'-splice sites during spliceosome assembly. It also is required for ATP-dependent interactions of both U1 and U2 snRNPs with pre-mRNA. And it interacts with other spliceosomal components, via the RS domains, to form a bridge between the 5'- and 3'-splice site binding components, U1 snRNP and U2AF. It binds to purine-rich RNA sequences, either 5'-AGSAGAGTA-3' (S=C or G) or 5'-GTTCGAGTA-3' and can bind to beta-globin mRNA and commit it to the splicing pathway.


# References

Merdzhanova,G., Cell Death Differ. 15 (12), 1815-1823 (2008) Solis,A.S., J. Biol. Chem. 283 (35), 23619-23626 (2008) Donev,R., Mol. Psychiatry 12 (7), 681-690 (2007) Sureau,A., Proc. Natl. Acad. Sci. U.S.A. 89 (24), 11683-11687 (1992)

# **Images**



All lanes: Anti-SFRS2 Antibody (N-term) at 1:1000 dilution Lane 1: HepG2 whole cell lysate Lane 2: 293 whole cell lysate Lane 3: HL-60 whole cell lysate Lysates/proteins at 20 µg per lane. Secondary: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ASP1615) at 1/15000 dilution. Observed band size: 30 KDa Blocking/Dilution buffer: 5% NFDM/TBST.



Formalin-fixed and paraffin-embedded human lung carcinoma tissue reacted with SFRS2 antibody (N-term), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.